Cibus (CBUS) Valuation Rank


CBUS Cibus Inc CBUS
53 GF Score
Price $1.36
GF Value $2.04
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cibus Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Cibus Valuation Rank Related Terms

CBUS
53GF Score
Cibus Inc CBUS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cibus (CBUS) Overvalued in 2026?

Based on GuruFocus' analysis, Cibus stock appears to be undervalued. The current stock price of $1.36 is trading 33.3% below its estimated GF Value™ of $2.04. GuruFocus considers Cibus to be Possible Value Trap.

Key valuation signals for CBUS:

  • Valuation Rank:
  • GF Value™: $2.04 vs. price of $1.36 (33.3% below fair value)
  • GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the CBUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cibus Business Description

Address 6455 Nancy Ridge Drive, San Diego, CA, USA, 92121
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
53GF Score

Get the complete analysis for CBUS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price
$2.04
GF Value